

EU COVID-19 VACCINATION ADVERSE REACTIONS REPORT

Source: *EudraVigilance* – European Medicine Agency (EMA)/ European Union (EU) (DATED 28. DECEMBER 2022)

A. General introduction

This report is presenting the details of adverse reactions of the experimental Covid-19 vaccines from AstraZeneca (CHADOX1 NCOV-19), Pfizer (Tozinameran), Moderna (CX-024414) and Janssen (AD26.COV2.S), which have been registered in the adverse reactions reporting/registration system EudraVigilance of the European Medicine Agency (EMA) from the European Union.

From March 2021 till March 2022, these reporting/registration details from EudraVigilance have been documented on a weekly basis. And as of April 2022, the information is updated monthly. This report is updated on 4 June 2022. All detailed line listing data have been exported from the EudraVigilance reporting/registration datasystem and carefully stored in different datafiles worldwide.

Details are presented per country, per brand and per main reaction group and per age group. The total number of adverse reactions as well as the total number of individual cases is registered, and that gives an indication of the average adverse reactions per individual case.

The overall reported/registered numbers of adverse reactions and deaths is truly shocking, as you will see. Where during the Swine-Flu pandemic from 2009 "only" **60** deaths were enough to stop the injection campaign with the experimental "Pandemix"-vaccine..., we see now, during the COVID-19 pandemic, no appropriate action is taken to stop the injection campaign with the experimental COVID-19 mRNA vaccines, even when almost **5 Million** adverse reactions and almost **30 Thousand** deaths have been reported and registered in EudraVigilance.

The justified question therefore remains: "What is going on? And why has no appropriate action been taken?"

B. Underreporting

It is a well-known and documented fact that only a small percentage of all adverse reactions of vaccination adverse reactions are in fact reported in reporting/registration systems such as EudraVigilance. In order to estimate the real quantity of adverse reactions, it is therefore important to estimate the percentage of underreporting of EudraVigilance. The estimated underreporting of the EudraVigilance is in this report estimated at **94%** and 3 references have been used for determination of this percentage:

1. Under-reporting of adverse drug reactions: a systematic review (Lorna Hazall; Saad A W Shakir).
"In total, 37 studies using a wide variety of surveillance methods were identified from 12 countries. These generated 43 numerical estimates of under-reporting. The median under-reporting rate across the 37 studies was 94%."

Link: (https://pubmed.ncbi.nlm.nih.gov/16689555/)

2. Electronic Support for Public Health–Vaccine Adverse Event Reporting System (ESP:VAERS) (Harvard Pilgrim Health Care, Inc. / Lazarus, Ross, MBBS, MPH, MMed, GDCompSci, Michael Klompas, MD, MPH; Steve Bernstein).

"Fewer than 1% of vaccine adverse events are reported."

Link: (https://digital.ahrq.gov/sites/default/files/docs/publication/r18hs017045-lazarus-final-report-2011.pdf)

3. Vaccination Numbers vs Individual cases

Comparison of total number of fully vaccinated people per EU-country versus the total number of reporting/registration of individual cases of adverse reactions as reported in EudraVigilance.

Link: (See section H of this report and https://www.laenderdaten.de/gesundheit/corona-impfungen.aspx)

1,4



C. Overall data across 4 vaccines:

Overall <u>ABSOLUTE</u> numbers of adverse reactions due to injections with experimental mRNA-vaccines from AstraZeneca (CHADOX1 NCOV-19), Pfizer (Tozinameran), Moderna (CX-024414) and Janssen (AD26.COV2.S) as registered in EudraVigilance from starting injection campaign 2021 till 28th. December 2022:

1.	The total number of reported main group adverse reactions	•	4.928.737
	The total number of reported individual cases who suffered from these reactions	:	2.163.368
	The average number of main group adverse reaction per individual case	:	2,3
2.	The total number of reported main group adverse reactions leading to death	:	49.285
	The total number of reported deaths	•	29.677

The average number of main group adverse reactions leading to death

Overall <u>ESTIMATED REAL</u> numbers of adverse reactions due to injections with experimental mRNA-vaccines from AstraZeneca (CHADOX1 NCOV-19), Pfizer (Tozinameran), Moderna (CX-024414) and Janssen (AD26.COV2.S) **BASED ON UNDERREPORTING OF 94** % from starting injection campaign till 28th. December 2022:

1.	The total number of reported main group adverse reactions	:	82.145.617
	The total number of reported individual cases	:	36.056.133
	The average number of main group adverse reaction per individual case	:	2,3
2.	The total number of reported main group adverse reactions leading to death	:	821.417
	The total number of reported deaths	:	494.617
	The average number of main group adverse reactions leading to death	:	1,4

TOTAL NEGATIVE CORRECTED THIS WEEK

-230.199



TOTAL ADVERSE REACTIONS RELATED TO THE "VACCIN"-INJECTIONS (update 28-12-2022) COVID-19 VACCINE
ASTRAZ+B2:C33ENECA (CHADOX1 COVID-19 MRNA VACCINE
PFIZER-BIONTECH
TOZINAMERAN COVID-19 MRNA VACCINE COVID-19 VACCINE JANSSEN Reactions 94% under ADVERSE REACTIONS GROUPS correction 94% MODERNA (CX-024414) (AD26.COV2.5) NCOV-19) 2.051.700 2.438.483 123.102 146.309 Blood and lymphatic system disorders Cardiac disorders 19.406 92.296 4.007 Congenital, familial and genetic disorders Ear and labyrinth disorders 25.133 34.372 3.619 39.003 187.738 1.971 166 2.360 1.035.333 94.367 1.269.550 6.556.883 15.531 10.246 989 11.689 Gastrointestinal disorders 124.843 68.857 11.975 393.413 General disorders and administration site conditions
Hepatobiliary disorders
Immune system disorders
Infections and infestations 699.978 3.079 28.955 186.536 49.261 227 865 16.077 1.364.994 5.743 46.752 260.731 235.199 22.749.900 95.717 779.200 4.345.517 19.182 Injury, poisoning and procedural complications Investigations Metabolism and nutrition disorders Musculoskeletal and connective tissue disorders 6.196 -8.53 46.844 12.505 1.719 67.264 1.121.067 33.957 15.398 204.545 64.447 17.039 304.713 3.455 19.525 126.177 2.102.950 110.840 642.253 5.817 22.155 Neoplasms benign, malignant and unspecified (incl cysts and polyps) 1.197 3.433 414.407 3.561 346 47.964 9.771 Nervous system disorders
Pregnancy, puerperium and perinatal conditions
Product issues
Psychiatric disorders 73.968 751 217 21.805 181.11 145.700 30.447 11.075.367 664.522 5.625 752 87.310 93.750 12.533 1.455.167 1.175 39 2.676 -1.241 Renal and urinary disorders 20.150 335.833 2.891.417 Reproductive system and breast disorders Respiratory, thoracic and mediastinal disorders Skin and subcutaneous tissue disorders 27.733 35.616 47.231 173.485 200.152 229.996 14.176 122.684 3 335 867 119.874 236.267 Surgical and medical procedures Vascular disorders 3.679 30.923 13.329 1.370 821.683 32,429 59.777 17.651 4,846 114.703 1.911.717 -230.199 TOTALS 1.134.858 20.697 4.928.737 82.145.617 Individual Cases 364.729 541.476 1.186.700 70.463 2.163.368 36.056.133 1.785.116 LAST RUN 378.252 6,304,200 ABSOLUTE THIS RUN

Fig. 1

ADVERSE REACTIONS GROUPS	COVID-19 VACCINE ASTRAZ+82:C33ENECA (CHADOX1 NCOV-19)	COVID-19 MRNA VACCINE PFIZER-BIONTECH TOZINAMERAN	BIONTECH COVID-19 MRNA VACCINE COVID-19 VACCINE JANS		PFIZER-BIONTECH COVID-19 MRNA VACCINE COVID-19 VACCINE JANSSEN MODERNA (CX-024414) (AD26 COV2 S)		Total Deaths 94% under reporting	REALITY Based on correction 94% underreporting
Blood and lymphatic system disorders	366	337	151	73	927	15.45		
Cardiac disorders	1.022	3.388	1.426	275	6.111	101.85		
Congenital, familial and genetic disorders	13	66	17	3	99	1.65		
Ear and labyrinth disorders	8	22	8	3	41	68		
Endocrine disorders	8	13	6	2	29	48		
Eye disorders	34	65	42	16	157	2.61		
Gastrointestinal disorders	515	923	489	131	2.058	34.30		
General disorders and administration site conditions	2.251	6.358	4.062	928	13.599	226.65		
Hepatobiliary disorders	92	134	69	23	318	5.30		
Immune system disorders	49	159	45	12	265	4.41		
Infections and infestations	821	2.427	1.156	275	4.679	77.98		
Injury, poisoning and procedural complications	239	569	243	38	1.089	18.15		
Investigations	230	638	412	174	1.454	24.23		
Metabolism and nutrition disorders	151	411	299	89	950	15.83		
Musculoskeletal and connective tissue disorders	199	333	254	74	860	14.33		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	66	313	118	15	512	8.53		
Nervous system disorders	1.413	2.507	1.238	325	5.483	91.38		
Pregnancy, puerperium and perinatal conditions	24	84	14	1	123	2.05		
Product issues	1	4	3	12.7	8	13		
Psychiatric disorders	89	270	202	37	598	9.96		
Renal and urinary disorders	110	357	246	54	767	12.78		
Reproductive system and breast disorders	3	10	11	7	31	51		
Respiratory, thoracic and mediastinal disorders	1.283	2.511	1.343	410	5.547	92.45		
Skin and subcutaneous tissue disorders	82	210	118	17	427	7.11		
Social circumstances	11	30	45	8	94	1.56		
Surgical and medical procedures	46	320	228	105	699	11.65		
Vascular disorders	618	1.042	494	206	2.360	39.33		
Total Adverse Reactions registered leading to fatality/death	9.744	- 23.501 -	12.739 -	3.301 -	49.285	821.417		
Total individual line listings fatal /death cases	6.411	14.759	6.741	1.766	29.677	494.617		
AST RUN	5.846	13.502	6.265	1.466	27.079			
ABSOLUTE THIS RUN	565	1.257	476	300	2.598	43,300		

Fig. 2



D. Details regarding AstraZeneca (CHADOX1 NCOV-19)

Overall <u>ABSOLUTE</u> numbers of adverse reactions due to injections with experimental mRNA-vaccines from AstraZeneca (CHADOX1 NCOV-19), as registered in EudraVigilance from starting injection campaign 2021 till 28th. December 2022. (It is to be noted, that 230.199 previous registered adverse reactions have been deleted from the EudraVigilance database since 4th. Junie 2022!)

The total number of reported main group adverse reactions
 The total number of reported individual cases (Fig. 1)
 The average number of main group adverse reaction per individual case
 2,1

The total number of reported main group adverse reactions leading to death
 The total number of reported deaths
 The average number of main group adverse reactions leading to death
 1,5

Overall <u>ESTIMATED REAL</u> numbers of adverse reactions due to injections with experimental mRNA-vaccines from AstraZeneca (CHADOX1 NCOV-19) **BASED ON UNDERREPORTING OF 94** % from starting injection campaign 2021 till 28th. December 2022:

The total number of estimated real main group adverse reactions
 The total number of estimated real individual cases
 The average number of main group adverse reaction per individual case
 2,1

The total number of estimated real main group adverse reactions leading to death
 The total number of estimated real deaths
 The average number of main group adverse reactions leading to death
 162.400
 106.850
 1,5

Reaction Group / Age group	/.	a dependent of	Total Tree	AND TREE	, itee	2.2000 / 5	are o	,55 get	50 400	Total Serious Adverse Reactions absolute registrations	Total Adverse Reactions leading to Death. Absolute registrations		REALITY Based on correction 94% underreporting
Blood and lymphatic system disorders	1.208	8	6	6	6	12.342	2.332	162		16.070	366	2,28%	6.100
Cardiac disorders	175	27	4	15	22	18.471	427	265		19.406	1.022	5,27%	17.035
Congenital, familial and genetic disorders	53	5	2		1	210	32	2	-	305	13	4,26%	21
ar and labyrinth disorders	1.297	2	3	10	3	12.018	2.152	46		15,531	8	0,05%	13
indocrine disorders	78	1	- 1	-	35	690	115	4		888	8	0,90%	133
ye disorders	1.919	15	10	5	16	17.776	3.271	109		23.121	34	0,15%	56
Gastrointestinal disorders	7.628	67	90	77	100	101.518	14,922	441		124.843	515	0,41%	8.58
Seneral disorders and administration site conditions	21.461	230	197	189	232	311.083	45.817	1.347		380.556	2.251	0,59%	37.51
fepatobiliary disorders	92		-		-	878	276	22		1.268	92	7,26%	1.533
mmune system disorders	607	1	6	2	2	5.579	968	28		7.193	49	0,68%	817
nfections and infestations	3.063	37	35	29	38	4.558	10.869	553		19.182	821	4,28%	13.683
njury, poisoning and procedural complications	2.043	17	94	9	37	1.111	2.687	198		6.196	239	3,86%	3.983
nvestigations	2.812	14	18	12	15	25.582	5.171	333		33,957	230	0,68%	3.833
Metabolism and nutrition disorders	1.043	11	19	11	14	11.947	2.199	154		15.398	151	0,98%	2.517
Musculoskeletal and connective tissue disorders	12.299	114	91	97	109	171.231	20,205	399		204.545	199	0,10%	3.317
leoplasms benign, malignant and unspecified (incl cysts and polyps)	132	-			-	587	258	18		995	66	6,63%	1.100
Vervous system disorders	17.339	184	150	150	188	22.857	32.142	958		73.968	1.413	1,91%	23.550
regnancy, puerperium and perinatal conditions	95	3	1	-	- 1	636	16	- 1		751	24	3,20%	400
Product issues	36			-	12	148	30	3		217	1	0,46%	17
sychiatric disorders	2.025	10	29	17	12	19.129	336	247		21.805	89	0,41%	1.485
Renal and urinary disorders	384	3	2	2	1	3.579	1.022	87		5.080	110	2,17%	1.833
Reproductive system and breast disorders	2.373	6	7	8	10	16.075	392	17		18.888	3	0,02%	50
Respiratory, thoracic and mediastinal disorders	3.563	21	31	21	28	36.215	8.176	589		48.644	1.283	2,64%	21.383
Skin and subcutaneous tissue disorders	461	38	51	30	33	47.828	8.699	253		57.393	82	0.14%	1.367
iocial circumstances	233	2	1	-	1	2.029	268	16		2.550	11	0,43%	183
Surgical and medical procedures	585	1	1	2	3	2.281	768	38		3.679	46	1,25%	767
/ascular disorders	2.582	22	13	12	12	22.309	7,011	468		32.429	618	1,91%	10.300
otal adverse reactions registered	85.586	839	861	704	883	868.667	170.561	6.757		1.134.858	9.744	1,5	162,400
otal individual line listings fatal /death cases 2021	324	3	120		2	1.852	1.747	529			4.457	- 11	74.283
otal individual line listings fatal /death cases 2022	138	4	(40.0		1	1.015	674	122			1.954		32.567
otal individual line listings fatal /death cases to date	462	7	- 0	- 10	3	2.867	2.421	651			6.411		106.850
otal individual line listings fatal /death cases Last Run	383	6	-	1	3	2.590	2.248	615			5.846		
otal individual line listings fatal /death cases this run	79	1		-1	-	277	173	36			565		9.417
ndividual Cases suffering adverse reactions	36.928	310	341	286	320	422.059	78.055	3.177	541.476				9.024.600
est run	32.872	300	340	284	295	384.101	72.108	3.067	493.367				
his run	4.056	10	1	2	25	37.958	5.947	110	48.109				801.817
						Adverse R	Reactions per	Case	2,1				
								LAST RUN		1.280.160	9.033		



E. Details regarding Pfizer (Tozinameran)

Overall <u>ABSOLUTE</u> numbers of adverse reactions due to injections with experimental mRNA-vaccines from Pfizer (Tozinameran), as registered in EudraVigilance from starting injection campaign 2021 till 28th. December 2022:

The total number of reported main group adverse reactions
 The total number of reported individual cases (Fig. 1)
 The average number of main group adverse reaction per individual case
 2.720.697
 1.186.700
 2,3

The total number of reported main group adverse reactions leading to death
 The total number of reported deaths
 The average number of main group adverse reactions leading to death
 14.759
 1,6

Overall <u>ESTIMATED REAL</u> numbers of adverse reactions due to injections with experimental mRNA-vaccines from Pfizer (Tozinameran), **BASED ON UNDERREPORTING OF 94** % from starting injection campaign 2021 till 28th. December 2022:

The total number of estimated real main group adverse reactions
 The total number of estimated real individual cases
 The average number of main group adverse reaction per individual case
 2,3

The total number of estimated real main group adverse reactions leading to death : 391.683
 The total number of estimated real deaths : 245.983
 The average number of main group adverse reactions leading to death : 1,6

Reaction Group / Age group	j.	and the second	STEEDED 1	admiret !	1.1140 S	10 pt 10 10 10 10 10 10 10 10 10 10 10 10 10	0/6	ssee /	Street	Total Serious Adverse Reactions absolute registrations	Total Adverse Reactions leading to Death. Absolute registrations		REALITY Based on correction 94% underreporting
Blood and lymphatic system disorders	3.976	18	18	278	1.734	70.456	4.439	531		81.450	337	0	5.61
Cardiac disorders	5.389	22	15	255	3.711	68.449	11.968	2.487		92.296	3.388	0	56.46
Congenital familial and genetic disorders	195	32	7	4	33	454	117	18		860	66	0	1.10
Ear and labyrinth disorders	1.982	5	6	56	504	26.864	4.598	357		34.372	22	0	36
Endocrine disorders	251	2	1	7	43	2.942	346	27		3.619	13	0	21
Eye disorders	2.348	.11	13	175	1.064	29.179	5.581	532		39.003	65	0	1.08
Gastrointestinal disorders	9.794	83	186	1.078	5.331	147,939	20.144	3.183		187.738	923	0	15.38
General disorders and administration site conditions	40.068	183	347	2.667	16.860	547.613	78.873	13.367		699.978	6.358	0	105.96
Hepatobiliary disorders	171	2	-	20	80	1.911	750	145		3.079	134	0	2.23
mmune system disorders	1.808	4	9	129	842	21.887	3.790	486		28.955	159	0	2.650
infections and infestations	10.900	25	62	682	5.271	134.419	30.117	5.060		186.536	2.427	0	40.45
Injury poisoning and procedural complications	5.707	113	380	297	1.052	30.714	7.537	1.044		46.844	569	0	9.48
nvestigations	4.011	12	28	210	2.078	45.616	10.276	2.216		64,447	638	0	10.63
Metabolism and nutrition disorders	1.069	11	53	154	601	10.799	3.404	948		17.039	411	0	6.856
Musculoskeletal and connective tissue disorders	17.962	67	42	522	4.513	246.703	32.103	2.801		304.713	333	0	5.550
Neoplasms benign malignant and unspecified (incl cysts and polyps)	436	1		11	66	1.761	1.009	171		3,455	313	0	5.21
Nervous system disorders	23.874	118	125	1.578	10.874	327,705	43.992	6.141		414.407	2.507	0	41.78
Pregnancy puerperium and perinatal conditions	564	27	4	-	9	2.945	12			3.561	84	0	1.40
Product issues	52	-		1	11	215	57	10		346	4	0	6
Psychiatric disorders	3.279	24	79	152	924	36.044	6.156	1.306		47.964	270	0	4.50
Renal and urinary disorders	647	1		48	287	6.147	2.140	501		9.771	357	0	5.950
Reproductive system and breast disorders	8.215	10	9	65	3.036	110.245	1.034	70		122.684	10	0	16
Respiratory thoracic and mediastinal disorders	6.152	37	59	423	3,276	80.468	15.844	3.349		109.608	2.511	0	41.850
Skin and subcutaneous tissue disorders	7.063	39	87	831	3.219	89.051	17.237	2.347		119.874	210	0	3,50
Social circumstances	566	-	-	28	187	5.688	805	124		7.398	30	0	500
Surgical and medical procedures	3.993	2	2	9	144	21.053	5.328	392		30.923	320	0	5.33
Vescular disorders	3.517	10	12	183	1,274	40.098	12.374	2,309		59.777	1.042	0	17.36
otal adverse reactions registered	163.989	859	1.544	9.863	67.024	2.107.365	320.031	50.022		2.720.697	23.501	1,6	391.683
Total individual line listings fatal /death cases 2021	654	12	4	1	59	1.849	4.048	3.301			9.928		165.467
otal individual line listings fatal /death cases 2022	341	10	4	33	94	1.460	1.958	931			4.831		80.517
otal individual line listings fatal /death cases to date	995	22	8	34	153	3.309	6.006	4.232			14.759		245.983
Total individual line listings fatal /death cases Last Run	860	18	6	18	121	2.929	5.516	4.034			13.502		
otal individual line listings fatal /death cases this run	135	4	2	16	32	380	490	198			1.257		20.950
ndividual Cases suffering adverse reactions	72.809	381	681	4.978	30,761	902.669	148.671	25.750	1.186.700				19.778.333
ast run	54.752	323	622	3,949	25.846	737.993	124.454	23.925	971.864				
This run	18.057	58	59	1.029	4.915	164.676	24.217	1.825	214.836				3.580.600
						Adverse Re	eactions per Cas	•	2,3				
								LAST RUN		2.244.030	21.333		
							6.00	OLUTE THIS R	W200	476.667	2.168		36.133

Fig. 4



F. Details regarding Moderna (CX-024414)

Overall <u>ABSOLUTE</u> numbers of adverse reactions due to injections with experimental mRNA-vaccines from Moderna (CX-024414), as registered in EudraVigilance from starting injection campaign 2021 till 28th. December 2022:

The total number of reported main group adverse reactions
 The total number of reported individual cases (Fig. 1)
 The average number of main group adverse reaction per individual case
 2,5

The total number of reported main group adverse reactions leading to death
 The total number of reported deaths
 The average number of main group adverse reactions leading to death
 12.739
 6.741
 1,9

Overall <u>ESTIMATED REAL</u> numbers of adverse reactions due to injections with experimental mRNA-vaccines from Moderna (CX-024414), **BASED ON UNDERREPORTING OF 94** % from starting injection campaign 2021 till 28th. December 2022:

The total number of estimated real main group adverse reactions
 The total number of estimated real individual cases
 The average number of main group adverse reaction per individual case
 2,5

The total number of estimated real main group adverse reactions leading to death : 212.317
 The total number of estimated real deaths : 112.350
 The average number of main group adverse reactions leading to death : 1,9

Second and lymphatic system disorders	Reaction Group / Age group	/.	at specified	2-leader 24	Selle 180	, ites	2.24	5.00.00	5-15-80 6	,0	Total Serious Adverse Reactions absolute	Total Adverse Reactions leading to Death. Absolute		REALITY Based on correction 94% underreporting
Carelise disorders									/ /	/				
Compensite, familial and genetic disorders				1									0,64%	2.51
Ear and lelyymth disorders				-					-				4,66% 6,14%	23.7
Inflacement discorders 50 - - 1 803 127 8 959 6				3								17	0,08%	1
1				1								6	0,61%	1
Application of the Committee of the Co													0,36%	7
April Apri													0,71%	8.1
Properties Pro													1,73%	67.70
Immune system disorders 533 2 2 2 73 7.565 1.455 107 9.799 45				99									5,90%	1.15
Infections and infestations 1,592 7 7 13 122 27,348 8,177 1,470 98,956 1,156 1,156 1,156 1,157 1	A Company of the Comp			2									0,46%	71
Injury, polisoning and procedural complications 985 20 98 12 115 7.992 2.790 499 12.055 1													2,97%	19.20
Investigations													1,94%	4.05
Metabolism and nutrition disorders		-									-		2,11%	6.86
Musculasaletal and connective tissue disorders		7.55					30,710,70	7719.50			30,000	77,000	4,30%	4.98
Neoplasms benign, malignant and unspecified (incl cysts and polyps) 132													0.23%	4.2
Nervous system disorders 5.688 33 26 49 999 119.225 18.013 1.667 145.700 1.238 Pregnancy, purperhum and perinatal conditions 91 4 2 - 1 1.073 4 - 1.175 1.189 1.190 1.238 Psychiatric disorders 20 - 1 1 1 1 1 1 1 1 1													9,86%	1.96
Pregnancy, puerperlum and perinatal conditions 91 4 2 1 1 1.073 4 1 1.075 14 Product issues 20 - 1 1 1 1.073 4 4 150 3 Product issues 20 - 1 1 1 1 89 34 4 150 3 Product issues 3 17 5 74 10.068 2.696 444 114.655 3 17 5 74 10.068 2.696 444 114.655 3 17 5 74 10.068 2.696 444 114.655 3 17 5 74 10.068 2.696 444 114.655 3 17 5 74 10.068 2.696 444 114.655 3 19 12 2.25 2.55 39 2.23 1.05 2.25 2.27.783 3 11 3 2.55 4 340 2.2 2.27.783 3 11 3 2.55 4 340 2.2 2.27.783 3 11 3 2.55 4 340 2.2 2.27.783 3 11 3 2.55 4 340 2.2 2.27.783 3 11 3 3.5 6 6 1.349 3 1 1 1 2 2.25 2.55 39 7.23 1 1.127 3.56 6 1.349 3 1 1 2 2.25 2.55 39 7.23 1 1.127 3.56 6 1.349 3 1 2 2.25 2.55 39 7.23 1 1.127 3.56 6 1.349 3 1 3 3 2 2.50 2.55 39 7.23 1 1.127 3.56 6 1.349 3 1 3 3 2 2.50 2.55 39 7.23 1 1.127 3.56 6 1.349 3 1 3 3 2 2.50 2.55 39 7.23 1 1.127 3.56 6 1.349 3 2 2 3 2 2.57 39 1 3.50 2 45 3 3 2 3 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3			33	26	49								0.85%	20,63
Product issues 20									- CONT.				1,19%	29
Psychiatric disorders			- 1		1			34					2,00%	5
Renal and urinary disorders Reproductive system and breast disorders 1.644 3 - 151 2.556 349 22 2.733 11. Reproductive system and breast disorders 1.644 3 - 151 2.556 349 22 2.733 11. Reproductive system and breast disorders 1.648 5 19 12 225 25.539 7.231 1.127 35.618 Solin and subcutaneous tissue disorders 2.120 15 23 28 316 37.574 6.620 535 47.231 11. Social skrumarcaes 141 - 1 - 9 2.707 533 91 3.502 Surgical and medical procedures 754 1 9 1 40 10.585 1.752 167 13.339 2.238 Vascular disorders 775 1 9 1 9 1 40 10.585 1.752 167 13.339 2.238 Vascular disorders 7723 4 3 2 67 12.140 4.174 538 17.651 4.941 Total and verse reactions registered 37.677 246 390 313 5.269 711.051 12.5066 13.940 893.952 Total individual line listings fatal /death cases 2021 151 2 1 - 7 1.339 2.550 1.144 Total individual line listings fatal /death cases 2022 112 4 2 3 21 593 598 234 Total individual line listings fatal /death cases to date 263 6 3 3 28 1.932 3.128 1.378 Total individual line listings fatal /death cases to date 263 6 3 3 28 1.932 3.128 1.378 Total individual line listings fatal /death cases to date 263 6 3 3 2 1 593 598 234 Total individual line listings fatal /death cases to date 263 6 3 3 2 8 1.932 3.128 1.378 Total individual line listings fatal /death cases to date 263 6 3 3 2 8 1.932 3.128 1.378 Total individual line listings fatal /death cases to date 263 6 3 3 2 8 1.932 3.128 1.378 Total individual line listings fatal /death cases to date 263 6 3 3 2 8 1.932 3.128 1.378 Total individual line listings fatal /death cases to date 263 6 3 3 3 28 1.932 3.128 1.378 Total individual line listings fatal /death cases to date 263 6 3 3 3 28 1.932 3.128 1.378 Total individual line listings fatal /death cases to date 263 6 3 3 3 28 1.932 3.128 1.378 Total individual line listings fatal /death cases to date 263 6 3 3 3 28 1.932 3.128 1.378 Total individual line listings fatal /death cases to date 263 6 5 3 3 3 2.88 1.932 2.959 1.317 Total individual line listings fatal /death cases to date 263 6			3	17					444			202	1,36%	3.36
Reproductive system and breast disorders		149			2	18	2,740	1.368	229		4,506		5,46%	4.10
Respiratory, thoracks and mediastriand disorders 1.458 5 9 12 225 25.539 7.231 1.127 35.616 1.143 1.143 1.143 1.144 1.14	roductive system and breast disorders	1.644	3		-	151	25,564	349	22		27.733	11	0.04%	18
Social circumstances	piratory, thoracic and mediastinal disorders	1.458	5	19	12	225	25.539	7.231	1.127		35.616	1.343	3,77%	22.38
Surgical and medical procedures 754 1 9 1 40 10.585 1.752 187 13.329 17.651 149 1 40 10.585 1.752 187 13.329 17.651 149 17.651 17.	and subcutaneous tissue disorders	2.120	15	23	28	316	37.574	6.620	535		47.231	113	0,25%	1.96
Vascular disorders 723 4 3 2 67 12,140 4,174 5,58 17,651 17,65	al circumstances	141	-	1	-	9	2.707	553	91		3.502	45	1,28%	75
Total adverse reactions registered 37.677 246 390 313 5.260 711.051 125.066 13.90 893.952 12.739 Total individual line listings fatal /death cases 2021 151 2 1 - 7 1.339 2.530 1.144 5174 Total individual line listings fatal /death cases 2022 112 4 2 3 21 593 598 234 1.567 Total individual line listings fatal /death cases to date 263 6 3 3 28 1.932 3.128 1.378 6.741 Total individual line listings fatal /death cases Last Run 198 4 3 2 13 1.769 2.959 1.317 6.265 Total individual line listings fatal /death cases this run 65 2 - 1 15 163 169 61 476 Individual Cases suffering adverse reactions 16.201 112 173 179 2.510 286.964 52.423 6.167 364.729 Last run 11.223 92 133 58 1.853 235.606 45.292 5.755 300.012 This run 4.978 20 40 121 657 51.358 7.131 412 64.717	cical and medical procedures	754	1	9	1	40	10.585	1.752	187		13.329	228	1,71%	3.80
Total individual line listings fatal /death cases 2021 151 2 1 - 7 1.339 2.530 1.144 5174 Total individual line listings fatal /death cases 2022 112 4 2 3 21 593 598 234 1.567 Total individual line listings fatal /death cases to date 263 6 3 3 28 1.932 3.128 1.378 6.741 Total individual line listings fatal /death cases to date 263 6 3 3 2 8 1.932 3.128 1.378 6.741 Total individual line listings fatal /death cases Last Run 198 4 3 2 13 1.769 2.959 1.317 6.265 Total individual line listings fatal /death cases this run 65 2 - 1 1 15 163 169 61 476 Last run 11.223 92 133 58 1.853 235.606 45.292 5.755 300.012 This run 4.978 20 40 121 657 51.358 7.131 412 64.717	cular disorders	723	4	3	2	67	12.140	4.174	538		17.651	494	2,80%	8.23
1.567 1.56	al adverse reactions registered	37.677	246	390	313	5.269	711.051	125.066	13.940		893.952	12.739	1,9	212.31
Fotal individual line listings fatal /death cases to date 263 6 3 3 28 1.932 3.128 1.378 6.741 Fotal individual line listings fatal /death cases Last Run 198 4 3 2 13 1.769 2.959 1.317 6.265 Fotal individual line listings fatal /death cases this run 65 2 - 1 1 15 163 169 61 476 Addividual Cases suffering adverse reactions 16.201 112 173 179 2.510 286.964 52.423 6.167 364.729 Last run 11.223 92 133 58 1.853 235.606 45.292 5.755 300.012 This run 4.978 20 40 121 657 51.358 7.131 412 64.717	al individual line listings fatal /death cases 2021	151		1			1.339	2.530	1.144			5174		86.23
Fotal individual line listings fatal /death cases Last Run 198 4 3 2 13 1.769 2.959 1.317	al individual line listings fatal /death cases 2022	112	4	2	3	21	593	598	234			1.567		26.117
Total individual line listings fatal /death cases this run 65 2 - 1 15 163 169 61 476 Additional line listings fatal /death cases this run 65 2 - 1 15 163 169 61 476 Additional line listings fatal /death cases this run 65 2 - 1 15 163 169 61 476 Additional line listings fatal /death cases this run 65 2 - 1 15 163 169 61 476 Additional line listings fatal /death cases this run 65 2 - 1 15 163 169 61 476 Additional line listings fatal /death cases this run 65 2 - 1 15 163 169 61 476 Additional line listings fatal /death cases this run 65 2 - 1 15 163 169 61 476 Additional line listings fatal /death cases this run 65 2 - 1 15 163 169 61 Additional line listings fatal /death cases this run 65 2 - 1 15 163 169 61 Additional line listings fatal /death cases this run 65 2 - 1 15 163 169 61 Additional line listings fatal /death cases this run 65 2 - 1 15 163 169 61 Additional line listings fatal /death cases this run 65 2 - 1 15 163 169 61 Additional line listings fatal /death cases this run 65 2 - 1 15 163 169 61 Additional line listings fatal /death cases this run 65 2 - 1 15 163 169 61 Additional line listings fatal /death cases this run 65 2 - 1 15 163 169 61 Additional line listings fatal /death cases this run 65 2 - 1 15 163 169 61 Additional line listings fatal /death cases this run 65 2 - 1 15 163 169 61 Additional line listings fatal /death cases this run 65 2 - 1 15 163 169 61 Additional line listings fatal /death cases this run 65 2 - 1 15 163 169 61 Additional line listings fatal /death cases this run 65 2 - 1 15 163 169 61 Additional line listings fatal /death cases this run 65 2 - 1 15 163 169 61 Additional line listings fatal /death cases this run 65 2 - 1 15 163 169 61 Additional line listings fatal /death cases this run 65 2 - 1 15 163 169 169 Additional line listings fatal /death cases this run 65 2 - 1 15 163 169 169 Additional line listings fatal /death cases this run 65 2 - 1 15 163 169 169 Additional line listings fatal /death cases this run 65 2 2 2 2 2 2 2 2 2 2 2 2 2 2	al individual line listings fatal /death cases to date	263				28	1.932	3.128	1.378			6.741		112.35
Individual Cases suffering adverse reactions 16.201 112 173 179 2.510 286.964 52.423 6.167 364.729 Last run 11.223 92 133 58 1.853 235.606 45.292 5.755 300.012 This run 4.978 20 40 121 657 51.358 7.131 412 64,717	al Individual line listings fatal /death cases Last Run	198	4	3	2	13	1.769	2.959	1.317			6.265		
Lest run 11.223 92 133 58 1.853 225.606 45.292 5.755 300.012 This run 4.978 20 40 121 657 51.358 7.131 412 64.717	al individual line listings fatal /death cases this run	65	2		1	15	163	169	61			476		7.93
This run 4.978 20 40 121 657 51.358 7.131 412 64.717	vidual Cases suffering adverse reactions	16.201	112	173	179	2.510	286.964	52.423	6.167	364.729				6.078.817
	run	11.223	92	133	58	1.853	235.606	45.292	5.755	300.012				
	run	4.978	20	40	121	657	51.358	7.131	412	64.717				1.078.61
Adverse Reactions per Case 2,5							Adverse	Reactions ne	r Case	2.5				-
LAST RUN 732,849 12,010											722 040	12.010		



G. Details regarding Janssen (AD26.COV2.S)

Overall <u>ABSOLUTE</u> numbers of adverse reactions due to injections with experimental mRNA-vaccines from Janssen (AD26.COV2.S), as registered in EudraVigilance from starting injection campaign 2021 till 28th. December 2022:

The total number of reported main group adverse reactions
 The total number of reported individual cases (Fig. 1)
 The average number of main group adverse reaction per individual case
 2,5

The total number of reported main group adverse reactions leading to death
 The total number of reported deaths
 The average number of main group adverse reactions leading to death
 1.766
 1,9

Overall <u>ESTIMATED REAL</u> numbers of adverse reactions due to injections with experimental mRNA-vaccines from Janssen (AD26.COV2.S), **BASED ON UNDERREPORTING OF 94** % from starting injection campaign 2021 till 28th. December 2022:

The total number of estimated real main group adverse reactions
 The total number of estimated real individual cases
 The average number of main group adverse reaction per individual case
 2.987.167
 1.174.383
 2.55

The total number of estimated real main group adverse reactions leading to death : 55.017
 The total number of estimated real deaths : 29.433
 The average number of main group adverse reactions leading to death : 1,9

Reaction Group / Age group	/	greden	D. J. Bederites J. F.	delle red >	ings /	2.780 3	, were	15 gr 54	e /	Total Serious Adverse Reactions absolute registrations	Total Advance Reactions leading to Death. Absolute registrations		REALITY Based on correction 94% underreporting
Blood and lymphatic system disorders	92	1		1	1	1.531	165	19		1.810	73	4,03%	1.217
Cardiac disorders	250	3	-	14	4	3.279	423	48		4.007	275	6,86%	4.583
Congenital, familial and genetic disorders	6	-	-	-	-	51	8	1		66	3	4,55%	50
Ear and labyrinth disorders	184	- F	1	12	2	1.651	125	8		1.971	3	0,15%	50
Endocrine disorders	15			18	+	137	13	1		166	2	1,20%	31
Eye disorders	175	-	-	- 12	2	1.966	205	12		2.360	16	0,68%	267
Gastrointestinal disorders	589	9	6	18	14	10.725	598	43		11.975	131	1,09%	2.183
General disorders and administration site conditions	3.090	8	16	4	81	43.445	2.390	227		49.261	928	1,88%	15.467
Hepatobiliary disorders	11	-	-	- 12	-	170	44	2		227	23	10,13%	383
Immune system disorders	88	1	-	74		704	69	3		865	12	1,39%	200
Infections and infestations	713	2	3		30	14.138	1.069	122		16.077	275	1,71%	4,583
Injury, poisoning and procedural complications	194	5	46	7.6	46	1.175	224	29		1.719	38	2,21%	633
Investigations	303		4	15.	5	6.907	940	89		8.248	174	2,11%	2.900
Metabolism and nutrition disorders	66	1	2	14.	2	874	179	32		1.156	89	7,70%	1.483
Musculoskeletal and connective tissue disorders	1.234	2	2	1	29	20.019	825	43		22.155	74	0,33%	1.233
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	24	-	-		-	112	33	1		170	15	8,82%	250
Nervous system disorders	1.806	3	7	3	47	27.004	1.463	114		30.447	325	1,07%	5.417
Pregnancy, puerperium and perinatal conditions	24		-			113	1			138	1	0,72%	17
Product issues	10	- 2		72-	4	23	6	14		39		0,00%	
Psychiatric disorders	239		5		1	2.180	226	25		2.676	37	1,38%	617
Renal and urinary disorders	52	*		75	1	597	124	19		793	54	6,81%	900
Reproductive system and breast disorders	310	1	-	-	3	3.822	41	3		4.180	7	0,17%	117
Respiratory, thoracic and mediastinal disorders	411	2	1	2	5	4.878	896	89		6.284	410	6,52%	6.833
Skin and subcutaneous tissue disorders	416	1	4	2	4	4.650	398	23		5.498	17	0,31%	283
Social circumstances	58	9		7.9	1	607	57	3		726	8	1,10%	133
Surgical and medical procedures	56		1 10	2.8	1	974	307	32		1.370	105	7,66%	1.750
Vascular disorders	426	1	2	1	9	3.615	713	79		4.846	206	4,25%	3.433
Total adverse reactions registered	10.842	31	99	14	288	155.347	11.542	1.067		179.230	3.301	1,9	55.017
Total individual line listings fatal /death cases 2021	142					473	356	72			1045		17.417
Total individual line listings fatal /death cases 2022	186				3	298	195	36			721		12.017
Total individual line listings fatal /death cases to date	328					771	551	108			1.766		29.433
Total individual line listings fatal /death cases Last Run	229	2	1	1	3	645	484	101			1.466		
otal individual line listings fatal /death cases this run	99				1	126	67	7			300		5.000
ndividual Cases suffering adverse reactions	4.974	17	56	6	118	60.408	4.477	407	70.463				1.174.383
ast run	4.285	13	52	5	101	52.614	3.898	370	61.338				
This run	689				17	7.794	579	37	9.125				152.083
						Adverse R	leactions per	Case	2,5				
								LAST RUN		156.991	2.940		
						-		The Lunia		22.239	361		6.017



H. Vaccination Numbers vs Reported individual cases of adverse reactions per EU-Country

Figure 7. shows an overview on the absolute number of vaccinated people per EU-country as reported by the German Ministery of Health (Bundesministerium für Gesundheid) and Zeitverlag Gerd Bucerius GmbH & Co. KG and shown on the websites:

Link: https://impfdashboard.de/

Link: https://www.zeit.de/wissen/gesundheit/corona-impfungen-aktuelle-zahlen-deutschland-karte

Link: https://www.laenderdaten.de/gesundheit/corona-impfungen.aspx

The comparison of the total number of fully vaccinated people versus the total number of individual cases of adverse reactions per EU country confirms clearly a grave underreporting.

Moreover – based on an average underreporting of 94 % - the overview shows that...:

1:9 vaccinated individuals suffered one or more adverse reactions.

1:669 vaccinated individuals have died from one or more adverse reactions

Based on these estimations, it is estimated that on a global scale, approximately **7.530.882 individuals died** to date, from the adverse reactions from the injections with COVID-19 mRNA vaccines from AstraZeneca (CHADOX1 NCOV-19), Pfizer (Tozinameran), Moderna (CX-024414) and Janssen (AD26.COV2.S).

And these numbers are still rising!!

Country EU	Number of individual cases ASTRAZENECA	Number of individual cases PFIZER	Number of individual cases MODERNA	Number of individual cases JANSSEN	Percentage Adv.Reactions Reported	Percentage of EU-population	Percentage fully vaccinated	Number of individuals fully vaccinated	Population
Germany	54223	211242	63919	11883	21,6%	18,7%	76,4%	64.417.899	84.316.62
Netherlands	37979	125482	49732	15052	14,4%	3,9%	68,5%	11.919.564	17.400.82
France	31850	126159	33232	1817	12,2%	15,2%	79,2%	54.097.677	68.305.14
Italy	23226	87028	19554	1712	8,3%	13,6%	79,6%	48.632.059	61.095.55
Austria	41262	107344	11213	11196	10,8%	2,0%	76,6%	6.827.425	8.913.08
Spain	16661	43529	19697	2386	5,2%	10,5%	86,3%	40.702.030	47.163.41
Sweden	24242	57816	22171	6	6,6%	2,3%	73,9%	7.747.415	10.483.64
Denmark	19808	28290	8574	472	3,6%	1,3%	81,9%	4.849.108	5.920.76
3elgium	9794	23700	7264	1786	2,7%	2,6%	79,5%	9.418.634	11.847.33
Portugal	8116	24633	3569	2089	2,4%	2,3%	86,4%	8.849.158	10.242.08
Poland	14828	17150	4073	2758	2,5%	8,4%	58,9%	22.436.836	38.093.10
Ireland	6104	10857	2246	559	1,3%	1,2%	82,4%	4.346.603	5.275.00
Czech Republic	1804	12895	1617	553	1,1%	2,4%	64,4%	6.894.267	10.705.38
Romania	6669	13572	2784	914	1,5%	4,1%	41,8%	7.741.318	18.519.89
Finland	2423	13574	3115	10	1,2%	1.2%	78.6%	4,402,816	5,601,54
Greece	2273	10068	1314	659	0,9%	2,3%	71,2%	7.500.116	10.533.87
Lithuania	2312	2436	684	528	0,4%	0.6%	67,3%	1.806.026	2.683.54
Estonia	2860	3241	696	391	0,5%	0.3%	63,8%	772.952	1.211.52
Croatia	1809	4072	830	419	0,5%	0.9%	55,2%	2.312.247	4.188.85
Slovenia	3624	6332	682	647	0,7%	0.5%	58.4%	1.227.105	2.101.20
Hungary	2213	3374	402	132	0,4%	2,2%	63,5%	6.159.231	9.699.57
Bulgaria	2255	1113	412	167	0,2%	1,5%	29,6%	2.034.483	6.873.25
Latvia	1137	1611	722	432	0,2%	0,4%	68,5%	1.261.925	1.842.22
Slovakia	2156	3920	855	247	0,5%	1,2%	47,2%	2.563.551	5.431.25
Luxembourg	327	1787	302	89	0,2%	0.1%	75.4%	490,374	650.36
Cyprus	348	846	345	24	0,1%	0,3%	73,7%	954.490	1.295.10
Malta	534	265	50	20	0,1%	0,1%	95,5%	443,298	464.18
Total	320837	942336	260054	56948	100,0%	100,0%	30,000	330.808.610	450.858.381
						and the same		73,4%	
A.		Total individual v	sccination damage corr	rected (due to 94% under	rreporting)			36.056.133	
		Total	deaths corrected (due	to 94% underreporting)				494.617	
		V	ACCINATION DAM	MAGE ONE IN:				9	
			DEATHS O	NE IN:				669	
			GLOBAL				64,80%	5.036.790.744	7.772.850.80

Fig. 7



I. Recommendations to Policy Makers, Health Officials and the General Public

- 1. The reported and registered ABSOLUTE numbers of adverse reactions caused by the injections with the experimental COVID-19 mRNA substances from AstraZeneca (CHADOX1 NCOV-19), Pfizer (Tozinameran), Moderna (CX-024414) and Janssen (AD26.COV2.S), the number of individual cases of people suffering from these adverse reactions and even death, are disastrous and beyond imagination. They must lead to an immediate total and worldwide ban of further injecting people with these dangerous substances.
- Estimated REAL numbers of the adverse reactions from these injections (due to severe underreporting), indicate that the reality of the damage caused by these injections is monstrous and even up to a scale of **WORLDWIDE GENOCIDAL PROPORTIONS**. Therefore, a full investigation of the disastrous consequences of the worldwide vaccination injection-campaign, by an International Investigation Committee of <u>totally independent</u> investigators, detectives, scientists, legists, jurors and representatives of both victims, non-vaccinated people and the general public has to be conducted. Since it is obvious that many policy makers, health care officials, officials from authorisation institutes, major shareholders of Media-, Big Tech-, and Pharmaceutical companies, et cetera, are directly or sideways involved in the matter of this injection-campaign, they should all be excluded from membership of this International Investigation Committee.
- 3. Based on the outcome and conclusions of the International Investigation Committee as above mentioned, all individuals who have participated directly or indirectly to the injection-campaign and carry responsibility for the disastrous health consequences and damage to individuals, must be brought to justice in an International Court of Justice or Special Dedicated Tribunal.